Economic analyses of diabetes interventions: Rationale, principles, findings, and interpretation

Endocrinologist

Volumn 9, Issue 2, 1999, Pages 113-117

  Herman, William H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN;

ARTICLE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG COST; DYSLIPIDEMIA; HEALTH CARE COST; HUMAN; HYPERTENSION; MASS SCREENING;

EID: 0032942970     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199903000-00008     Document Type: Article

References (15)

1. Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78: 809A-810F.
2. Gruber W, Lander T, Leese B, Songer T, Williams R (editors): The economics of diabetes and diabetes care: a report of the Diabetes Health Economics Study Group. Brussels, Belgium, International Diabetes Federation 1997.
3. Herman WH, Dasbach EJ, Songer TJ, Eastman RC: The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinol Metab Clin North Am 1997; 26: 679-95.
4. Gold MR, Siegel JE, Russell LB, Weinstein MC (editors): Cost-effectiveness in health and medicine. New York, Oxford University Press 1996.
5. Rubin RJ, Dietrich KA, Hawk AD: Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab 1998; 83: 2635-42.
6. CDC Diabetes Cost-Effectiveness Study Group: The cost-effectiveness of screening for type 2 diabetes. J Am Med Assoc 1998; 280: 1757-63.
7. The Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. J Am Med Assoc 1996; 276: 1409-15.
8. Eastman RC, Javitt JC, Herman WH, et al.: Model of complications of NIDDM. II. Analysis of the health benefit and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735-44.
9. Javitt JC, Aiello LP: Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996; 124: 164-9.
10. Rodby RA, Firth LM, Lewis EF, The Collaborative Study Group: An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 1996; 19: 1051-61.
11. UK Prospective Diabetes Study Group: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. Br Med J 1998; 317: 720-6.
12. Schwartz JS, Boccuzzi SJ, Glick H, et al.: Cost effectiveness of LDL-C reduction in diabetic CHD patients: implications from the Scandinavian Simastatin Survival Study (4S). Circulation 1997; 96: 2827A.
13. Hlatky MA, Rogers WJ, Johnstone I, et al.: Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 1997; 336: 92-9.
14. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81.
15. Tengs TO, Adams ME, Pliskin JS, et al.: Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90.